|
|
|
Clinical trials offer patients access to promising new treatments which have not yet been approved. They offer an opportunity to help make new treatments available to all patients by helping to advance science. Patients in clinical trials receive high-quality care and are carefully followed.
Click to view and/or download the slides for Step 10.
If commercially available drugs are not working, then new drugs available only within clinical trials may be recommended. Depending upon the circumstances, a patient may also seek to participate in a later phase clinical trial (e.g., phase III) even from the onset of the disease. ASH 2011 presentations that address STEP 10
REFERENCES The IMF is pleased to offer a number of ways to help you locate a clinical trial which may be appropriate.
|
|
Before new drugs or procedures can be approved for use in treating myeloma, they must go through clinical trials to prove that they are safe and more effective than currently-available treatments
|
|
|
The Myeloma Matrix lists drugs currently under development and tracks them from discovery to approval. |
|
|
|
|
|
Kyprolis ® (carfilzomib)is a next-generation proteasome inhibitor. It is FDA-approved for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies, including bortezomib and an
immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of the completion of the last therapy.
|
|
|
|
|
![]()
|
Elotuzumab is a monoclonal antibody that targets CS1, a cell surface glycoprotein highly expressed on myeloma cells but minimally expressed on normal cells. |
|
|
|
|
|
Like lenalidomide, Pomalyst® (pomalidomide) capsules is an immunomodulatory derivative (IMiD®) of thalidomide. Approved on February 8, 2013, it is well-tolerated in patients who have relapsed after multiple prior therapies and are refractory to both lenalidomide and bortezomib. |
|
|
|
|
|
REVLIMID®, a potent immunomodulatory derivative (IMiD) of thalidomide, induces apoptosis in resistant MM cell lines and patient cells and, more importantly, decreases binding of MM cells to bone marrow stromal cells. |
|
|
|
|
|
Thalidomide was prescribed to lessen the symptoms of morning sickness during the 1950s. It was taken off the market in 1961, when it was found to be a cause of birth defects. Today thalidomide is used in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma. |
|
|
|
|
|
The latest on VELCADE®—general information, clinical trials, webcasts, publications—is available on the VELCADE® Resource Page. |
|
|
|
|
|
Vorinostat is an HDAC inhibitor, which has shown promise in the treatment of multiple myeloma. |
|
|
|
|
![]()
|
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple
Myeloma Tumors for the Palliation of Pain in Patients Who Are Not Candidates for Radiation |
|
|
|
step 1: get the correct diagnosis
print
back to top